Peter Greenleaf
President and Chief Executive Officer
Replay available
Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q4 2025 earnings conference call, held 2026-02-26. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joe Miller
Chief Financial Officer
Dr. Greg Keenan
Chief Medical Officer
Joseph Schwartz
Analyst, Leerink Partners
Arthur He
Analyst, H.C. Wainwright
Sahil Dhingra
Analyst, RBC
David Martin
Analyst, Bloomberg
Olivia Breyer
Analyst, Cantor Fitzgerald
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aurinia Pharmaceuticals Inc.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.260 Good morning. Welcome to the Irinia Pharmaceuticals' fourth quarter and full year 2025 00:00:05.260 -- 00:00:10.729 conference call. Please be advised that a Q&A session will follow Irinia's prepared remarks, 00:00:10.729 -- 00:00:15.496 and we ask you please ask one question and one follow-up to return to the queue. 00:00:15.496 -- 00:00:19.543 I will now turn the call over to Peter Greenleaf, President and Chief Executive Officer 00:00:19.543 -- 00:00:23.607 of Irinia. Peter, please go ahead. 00:00:23.723 -- 00:00:28.090 Good morning. We want to thank you all for joining us today to discuss Arinia's fourth 00:00:28.090 -- 00:00:32.076 quarter and full year 2025 update. 00:00:32.076 -- 00:00:36.303 Joining me on the call today are Joe Miller, our Chief Financial Officer, and Dr. 00:00:36.303 -- 00:00:39.548 Greg Keenan, our Chief Medical Officer. 00:00:39.548 -- 00:00:44.616 On today's call, we will report fourth quarter and full year 2025 financial 00:00:44.616 -- 00:00:49.188 results and provide an update on recent business progress. 00:00:49.188 -- 00:00:55.799 During today's call, we may make forward-looking statements based on current expectations. 00:00:55.799 -- 00:01:01.449 These forward-looking statements are subject to a number of significant risks and uncertainties, 00:01:01.449 -- 00:01:05.312 and actual results may differ materially. 00:01:05.616 -- 00:01:10.404 We are pleased to have delivered strong Lucana sales in 2025, 00:01:10.404 -- 00:01:13.906 growing at a rate of 25% year-over-year. 00:01:14.737 -- 00:01:20.264 And for 2026, we expect net product sales of $305 million 00:01:20.264 -- 00:01:23.329 to $315 million, 00:01:23.329 -- 00:01:28.653 up 12 to 16% compared to 2025. 00:01:29.297 -- 00:01:34.123 And with...